Our research has indicated that CLPTM1L is a hub for multiple survival signaling pathways in tumor cells under oncogenic, genotoxic, and metabolic stress. We have filed an international patent application (PCT) on therapeutic monoclonal antibodies targeting CLPTM1L. The development of these therapeutics stemmed from the study of CLPTM1L as a determinant of cancer susceptibility and its role in tumorigenesis, and the discovery that this protein could be targeted at the surface of tumor cells. We have mechanism of action and striking in vivo preclinical data for these antibodies in models of pancreatic and lung cancer.
Essential BioTechnology
